These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31474719)

  • 1. The Prediction of the Area under the Curve and Clearance of Midazolam from Single-Point Plasma Concentration and Urinary Excretion in Healthy Volunteers.
    Miura M; Uchida S; Tanaka S; Inui N; Kawakami J; Watanabe H; Namiki N
    Biol Pharm Bull; 2019; 42(9):1590-1595. PubMed ID: 31474719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
    Chaobal HN; Kharasch ED
    Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam.
    Katzenmaier S; Markert C; Mikus G
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1137-41. PubMed ID: 20680253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    J Clin Pharmacol; 2005 Oct; 45(10):1187-97. PubMed ID: 16172184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers.
    Krupka E; Venisse N; Lafay C; Gendre D; Diquet B; Bouquet S; Perault MC
    Eur J Clin Pharmacol; 2006 Aug; 62(8):653-9. PubMed ID: 16832678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
    Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
    Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo.
    Lowry JA; Kearns GL; Abdel-Rahman SM; Nafziger AN; Khan IS; Kashuba AD; Schuetz EG; Bertino JS; van den Anker JN; Leeder JS
    Clin Pharmacol Ther; 2003 Mar; 73(3):209-22. PubMed ID: 12621386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration.
    Lin YS; Lockwood GF; Graham MA; Brian WR; Loi CM; Dobrinska MR; Shen DD; Watkins PB; Wilkinson GR; Kharasch ED; Thummel KE
    Pharmacogenetics; 2001 Dec; 11(9):781-91. PubMed ID: 11740342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam.
    Shord SS; Chan LN; Camp JR; Vasquez EM; Jeong HY; Molokie RE; Baum CL; Xie H
    Br J Clin Pharmacol; 2010 Feb; 69(2):160-6. PubMed ID: 20233179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
    Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
    Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of ticagrelor on the metabolism of midazolam in healthy volunteers.
    Teng R; Butler K
    Clin Ther; 2013 Jul; 35(7):1025-37. PubMed ID: 23870610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.
    Padhi D; Salfi M; Emery M
    Drugs R D; 2008; 9(5):335-43. PubMed ID: 18721002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity.
    Lee LS; Bertino JS; Nafziger AN
    J Clin Pharmacol; 2006 Feb; 46(2):229-34. PubMed ID: 16432275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex differences in CYP3A activity using intravenous and oral midazolam.
    Chen M; Ma L; Drusano GL; Bertino JS; Nafziger AN
    Clin Pharmacol Ther; 2006 Nov; 80(5):531-8. PubMed ID: 17112809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single plasma sampling to predict oral clearance of CYP3A probe midazolam.
    Zhu B; Ou-Yang DS; Cheng ZN; Huang SL; Zhou HH
    Acta Pharmacol Sin; 2001 Jul; 22(7):634-8. PubMed ID: 11749829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
    Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
    J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice.
    Farkas D; Oleson LE; Zhao Y; Harmatz JS; Zinny MA; Court MH; Greenblatt DJ
    J Clin Pharmacol; 2007 Mar; 47(3):286-94. PubMed ID: 17322140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase.
    Greenblatt DJ; Peters DE; Oleson LE; Harmatz JS; MacNab MW; Berkowitz N; Zinny MA; Court MH
    Br J Clin Pharmacol; 2009 Dec; 68(6):920-7. PubMed ID: 20002087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrasubject Variability in Intravenous and Oral Probes for Hepatic and First-Pass CYP3A Activity.
    Kharasch ED; Hoffer C; Bedynek P
    Clin Pharmacokinet; 2024 Aug; 63(8):1121-1135. PubMed ID: 39073723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping.
    Link B; Haschke M; Grignaschi N; Bodmer M; Aschmann YZ; Wenk M; Krähenbühl S
    Br J Clin Pharmacol; 2008 Oct; 66(4):473-84. PubMed ID: 18537963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.